TransMedics Group (TMDX) Projected to Post Earnings on Monday

TransMedics Group (NASDAQ:TMDX - Get Free Report) is anticipated to release its earnings data after the market closes on Monday, February 24th. Analysts expect TransMedics Group to post earnings of $0.22 per share and revenue of $109.49 million for the quarter. Persons interested in listening to the company's earnings conference call can do so using this link.

TransMedics Group Price Performance

TMDX stock traded down $3.97 during trading on Thursday, hitting $75.45. 1,448,042 shares of the company's stock traded hands, compared to its average volume of 2,216,569. TransMedics Group has a 52 week low of $55.00 and a 52 week high of $177.37. The stock has a market capitalization of $2.53 billion, a price-to-earnings ratio of 80.27 and a beta of 2.12. The business has a fifty day simple moving average of $66.28 and a 200 day simple moving average of $105.26. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20.

Insiders Place Their Bets

In related news, insider Tamer I. Khayal sold 1,084 shares of the business's stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $86.40, for a total value of $93,657.60. Following the completion of the sale, the insider now owns 20,843 shares in the company, valued at approximately $1,800,835.20. The trade was a 4.94 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 7.00% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on TMDX. Canaccord Genuity Group reduced their price objective on TransMedics Group from $109.00 to $104.00 and set a "buy" rating on the stock in a research note on Wednesday, November 20th. Piper Sandler dropped their target price on TransMedics Group from $110.00 to $90.00 and set an "overweight" rating for the company in a report on Wednesday, December 11th. Robert W. Baird decreased their price target on TransMedics Group from $150.00 to $120.00 and set an "outperform" rating on the stock in a report on Wednesday, December 11th. JPMorgan Chase & Co. reaffirmed a "neutral" rating and set a $75.00 price objective (down from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th. Finally, Oppenheimer reissued an "outperform" rating and issued a $125.00 target price on shares of TransMedics Group in a research note on Tuesday, December 3rd. Three analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $122.70.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.